Bruno Flamion

Bruno Flamion, MD/PhD, holds a medical degree from the University of Brussels, with a specialisation in Internal Medicine.

His main activity, since 2016, is Senior Vice-President, Head of Strategic Development at Idorsia Pharmaceuticals, an innovative biotech company located close to Basel, Switzerland, where he takes an active part in the development and regulatory approval of several novel chemical compounds in different fields (insomnia, resistant hypertension, systemic lupus erythematosus, etc.).

Bruno has been Professor of Physiology and Clinical Pharmacology at the University of Namur, Belgium since 1996. He headed the Laboratory of Physiology and Pharmacology of that university for twenty years (1996-2016), focusing his research on the kidney interstitial matrix and especially hyaluronan, a long unbranched polymer involved in inflammatory conditions and cancer. Before that, he was Research Associate at the National Institutes of Health, Bethesda, MD, USA (1988-1992), and at the Belgian National Fund for Scientific Research (1992-1996).

Bruno also worked part-time for and at the European Medicines Agency, London, UK, for 12 years (2000-2012), representing Belgium in different committees including the Committee for Human Medicinal Products, and the Scientific Advice Working Party which he chaired for 6 years. In Belgium, he chaired the Committee for Reimbursement of Medicines for 3 years (2010-2012). Bruno is convinced the needs of researchers, industry, regulatory agencies, social security systems and patients can be fulfilled in parallel.